Department of Psychiatry, University of Missouri, Kansas City, MO, USA.
Department of Psychiatry, Sechenov University, Unica Medical Center, Moscow, Russia.
Braz J Psychiatry. 2022 Nov 5;44(5):522-531. doi: 10.47626/1516-4446-2021-2446. Epub 2022 Jun 21.
Over the past 15 years, the increasing nonmedical use of tropicamide ophthalmic drops has been reported in Europe, coinciding with an increase in opioid addiction and drug-related mortality. Although tropicamide is generally known as a cheap alternative to heroin in Eastern Europe, it still appears to be a relatively new phenomenon that has arisen over the last decade. A narrative review was conducted of all the relevant sources published in more than five countries between January 1, 1975 and January 10, 2021. For bibliographic accuracy, the materials published in Russian and Italian were professionally translated to English. During the preparation of this report, we were able to interview five Russian-speaking patients who injected tropicamide in the past and we discuss another case of intravenous tropicamide use. This review was acknowledged by the institutional review board of the University of Missouri-Kansas City. All patients interviewed at the Unica Medical Center consented for their clinical information to be reported in a medical publication. We analyzed data from 50+ various sources and covered a variety of drug-related issues, including information on the extent, patterns, and trends in tropicamide use, its health consequences, and other clinical findings. The information provided in this article may help providers better detect tropicamide abuse and incorporate new rehabilitation strategies into the management of these patients.
在过去的 15 年中,欧洲越来越多地报告了托吡卡胺滴眼剂的非医疗用途,这与阿片类药物成瘾和与药物相关的死亡率增加相吻合。虽然托吡卡胺通常被认为是东欧地区海洛因的廉价替代品,但它似乎仍然是过去十年出现的相对较新的现象。对 1975 年 1 月 1 日至 2021 年 1 月 10 日期间在五个以上国家/地区发表的所有相关来源进行了叙述性综述。为了确保书目准确性,俄语和意大利语发表的材料被专业翻译成英语。在编写本报告期间,我们能够采访过去注射过托吡卡胺的五名俄语患者,并讨论了另一个静脉内使用托吡卡胺的案例。这项审查得到了密苏里大学堪萨斯城分校机构审查委员会的认可。在 Unica 医疗中心接受采访的所有患者都同意将他们的临床信息报告在医学出版物中。我们分析了来自 50 多个不同来源的数据,并涵盖了各种与药物相关的问题,包括托吡卡胺使用的范围、模式和趋势、其健康后果以及其他临床发现的信息。本文提供的信息可能有助于提供者更好地发现托吡卡胺滥用,并将新的康复策略纳入这些患者的管理中。